JUVÉDERM references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
HArmonyCa Lidocaine
HArmonyCa Lidocaine is a dual-effect injectable for facial soft tissue augmentation. It targets age-related volume loss and contour changes, delivering an immediate lifting effect with sustained collagen support to restore facial structure.
HArmonyCa Lidocaine is a hybrid hyaluronic acid and calcium hydroxyapatite injectable facial implant for the Allergan Aesthetics range, also referred to as HArmonyCa filler or harmonyca dermal filler. It is intended for facial soft tissue augmentation and is placed in the deep dermal and sub-dermal layers, commonly in the cheeks and along the jawline. The hyaluronic acid gives an immediate lifting and volumising effect while the calcium hydroxyapatite microspheres support sustained collagen stimulation, so a single treatment delivers both an instant result and progressive structural support. The composition is calcium hydroxyapatite microspheres of 25 to 45 microns at 55.7%, cross-linked sodium hyaluronate gel at 20 mg/mL, phosphate buffer, and lidocaine hydrochloride at 3 mg/mL (0.3%) to reduce pain during treatment. It is supplied as two 1.25 mL pre-filled glass syringes with two single-use 27G half-inch thin-wall sterile needles, is a CE-marked medical device, and is for professional use by authorised medical practitioners only.
Key Benefits of HArmonyCa Lidocaine
- Provides an immediate lifting and volumising effect through hyaluronic acid
- Supports sustained collagen stimulation through calcium hydroxyapatite
- Combines hyaluronic acid and calcium hydroxyapatite in one ready-to-use injectable
- Designed for facial soft tissue augmentation in the deep dermal and sub-dermal layers
- Contains 0.3% lidocaine hydrochloride to reduce pain during treatment
- Supplied as two 1.25 mL pre-filled syringes with two 27G thin-wall needles
- CE-marked medical device
Indications and Professional Use
Main indications
- Facial soft tissue augmentation
- Deep dermal and sub-dermal facial volume augmentation
Professional use
For use only by authorised medical practitioners in accordance with local regulation, under sterile conditions, following clinical assessment. Single use, single patient; do not re-sterilise. The manufacturer's Instructions for Use specify insertion at approximately 30 degrees into the deep dermis with the bevel oriented downwards, using a linear threading technique, and cross-hatching in layers where larger volumes are required. Aspirate before injecting. Subsequent treatments may be required, with at least seven days between treatments to allow evaluation of the outcome, and at least four weeks between ultrasound-based, laser or peeling treatments and use of this product. It is contraindicated in pregnancy or breastfeeding, in patients under 18, and in patients with known sensitivity to any product component or to lidocaine or other amide-type local anaesthetics. It is also contraindicated in skin disease or abnormal skin conditions, acute or chronic infection or inflammation at or near the treatment site, susceptibility to keloid or hypertrophic scarring, impaired wound healing, prolonged bleeding, a history of anaphylaxis or multiple severe allergies, known sensitivity to steroids, herpes, and autoimmune disease.
Treatment areas
- Cheeks
- Jawline
- Other facial soft-tissue areas as determined by the authorised practitioner and permitted by the Instructions for Use
Patient profile
Patients aged 18 years or older who are suitable for facial soft tissue augmentation following clinical assessment by an authorised medical practitioner. Contraindicated during pregnancy and breastfeeding, and in patients meeting the other exclusion criteria specified in the manufacturer's Instructions for Use, including known sensitivity to any product component or to amide-type local anaesthetics. The manufacturer notes that safety and efficacy have not been evaluated in diabetic patients, in patients previously treated with other filling implants, or in patients with a history of keloid formation, connective tissue disease, active bleeding disorders, active hepatitis, cancer, stroke or myocardial infarction, or on immunosuppressive therapy.
How HArmonyCa Lidocaine Works
HArmonyCa combines cross-linked hyaluronic acid and calcium hydroxyapatite in a single injectable. The hyaluronic acid component provides an immediate lifting and volumising effect, while the calcium hydroxyapatite microspheres, at 25 to 45 microns and 55.7% of the formulation, support sustained collagen stimulation and provide progressive structural support after treatment. The 0.3% lidocaine hydrochloride reduces pain during treatment. The implant is placed in the deep dermal and sub-dermal layers and is biodegradable.
Why Order From Allpara
Allpara offers genuine, verified HARMONYCA products from vetted suppliers, with full batch-traceability and expert support. We serve clinics and aesthetic professionals with CE-certified products, fast EU-wide delivery from our EU warehouse, and competitive trade pricing. Our focus is your patients' safety, satisfaction and results - with dedicated after-sales support for your peace of mind.
Frequently Asked Questions
What is in HArmonyCa?
Calcium hydroxyapatite microspheres of 25 to 45 microns diameter at 55.7%, suspended in a cross-linked sodium hyaluronate gel at 20 mg/mL from a non-animal source, with a phosphate buffer and lidocaine hydrochloride at 3 mg/mL.
How does HArmonyCa differ from a standard hyaluronic acid filler?
HArmonyCa combines cross-linked hyaluronic acid for immediate volume with calcium hydroxyapatite microspheres for sustained collagen stimulation, giving it a dual mechanism that standard single-ingredient hyaluronic acid fillers do not have.
How long do HArmonyCa results last?
The manufacturer's EU Instructions for Use state no duration of effect. It notes that subsequent treatments may be required to obtain optimal results, with at least seven days between treatments so the outcome of the implantation can be evaluated.
More from Allergan
Clinic alternatives
Pick up where you left off
HArmonyCa Lidocaine
HArmonyCa Lidocaine is a hybrid hyaluronic acid and calcium hydroxyapatite injectable facial implant for the Allergan Aesthetics range, also referred to as HArmonyCa filler or harmonyca dermal filler. It is intended for facial soft tissue augmentation and is placed in the deep dermal and sub-dermal layers, commonly in the cheeks and along the jawline. The hyaluronic acid gives an immediate lifting and volumising effect while the calcium hydroxyapatite microspheres support sustained collagen stimulation, so a single treatment delivers both an instant result and progressive structural support. The composition is calcium hydroxyapatite microspheres of 25 to 45 microns at 55.7%, cross-linked sodium hyaluronate gel at 20 mg/mL, phosphate buffer, and lidocaine hydrochloride at 3 mg/mL (0.3%) to reduce pain during treatment. It is supplied as two 1.25 mL pre-filled glass syringes with two single-use 27G half-inch thin-wall sterile needles, is a CE-marked medical device, and is for professional use by authorised medical practitioners only.
Key Benefits of HArmonyCa Lidocaine
- Provides an immediate lifting and volumising effect through hyaluronic acid
- Supports sustained collagen stimulation through calcium hydroxyapatite
- Combines hyaluronic acid and calcium hydroxyapatite in one ready-to-use injectable
- Designed for facial soft tissue augmentation in the deep dermal and sub-dermal layers
- Contains 0.3% lidocaine hydrochloride to reduce pain during treatment
- Supplied as two 1.25 mL pre-filled syringes with two 27G thin-wall needles
- CE-marked medical device
Indications and Professional Use
Main indications
- Facial soft tissue augmentation
- Deep dermal and sub-dermal facial volume augmentation
Professional use
For use only by authorised medical practitioners in accordance with local regulation, under sterile conditions, following clinical assessment. Single use, single patient; do not re-sterilise. The manufacturer's Instructions for Use specify insertion at approximately 30 degrees into the deep dermis with the bevel oriented downwards, using a linear threading technique, and cross-hatching in layers where larger volumes are required. Aspirate before injecting. Subsequent treatments may be required, with at least seven days between treatments to allow evaluation of the outcome, and at least four weeks between ultrasound-based, laser or peeling treatments and use of this product. It is contraindicated in pregnancy or breastfeeding, in patients under 18, and in patients with known sensitivity to any product component or to lidocaine or other amide-type local anaesthetics. It is also contraindicated in skin disease or abnormal skin conditions, acute or chronic infection or inflammation at or near the treatment site, susceptibility to keloid or hypertrophic scarring, impaired wound healing, prolonged bleeding, a history of anaphylaxis or multiple severe allergies, known sensitivity to steroids, herpes, and autoimmune disease.
Treatment areas
- Cheeks
- Jawline
- Other facial soft-tissue areas as determined by the authorised practitioner and permitted by the Instructions for Use
Patient profile
Patients aged 18 years or older who are suitable for facial soft tissue augmentation following clinical assessment by an authorised medical practitioner. Contraindicated during pregnancy and breastfeeding, and in patients meeting the other exclusion criteria specified in the manufacturer's Instructions for Use, including known sensitivity to any product component or to amide-type local anaesthetics. The manufacturer notes that safety and efficacy have not been evaluated in diabetic patients, in patients previously treated with other filling implants, or in patients with a history of keloid formation, connective tissue disease, active bleeding disorders, active hepatitis, cancer, stroke or myocardial infarction, or on immunosuppressive therapy.
How HArmonyCa Lidocaine Works
HArmonyCa combines cross-linked hyaluronic acid and calcium hydroxyapatite in a single injectable. The hyaluronic acid component provides an immediate lifting and volumising effect, while the calcium hydroxyapatite microspheres, at 25 to 45 microns and 55.7% of the formulation, support sustained collagen stimulation and provide progressive structural support after treatment. The 0.3% lidocaine hydrochloride reduces pain during treatment. The implant is placed in the deep dermal and sub-dermal layers and is biodegradable.
Why Order From Allpara
Allpara offers genuine, verified HARMONYCA products with full batch-traceability, CE-certified stock, fast EU-wide delivery and expert after-sales support.
Frequently Asked Questions
What is in HArmonyCa?
Calcium hydroxyapatite microspheres of 25 to 45 microns diameter at 55.7%, suspended in a cross-linked sodium hyaluronate gel at 20 mg/mL from a non-animal source, with a phosphate buffer and lidocaine hydrochloride at 3 mg/mL.
How does HArmonyCa differ from a standard hyaluronic acid filler?
HArmonyCa combines cross-linked hyaluronic acid for immediate volume with calcium hydroxyapatite microspheres for sustained collagen stimulation, giving it a dual mechanism that standard single-ingredient hyaluronic acid fillers do not have.
How long do HArmonyCa results last?
The manufacturer's EU Instructions for Use state no duration of effect. It notes that subsequent treatments may be required to obtain optimal results, with at least seven days between treatments so the outcome of the implantation can be evaluated.